

# Contents

Feature Boxes . . . . .	xv
Preface to the Second Edition . . . . .	xvii
Preface to the First Edition . . . . .	xix
Acknowledgments . . . . .	xxi
About the Companion Website . . . . .	xxiii
<b>1 Inorganic Chemistry Basics . . . . .</b>	<b>1</b>
1.1 Introduction . . . . .	1
1.2 Crystal Field Theory . . . . .	1
1.2.1 Octahedral Crystal Field . . . . .	2
1.2.2 Other Crystal Fields . . . . .	6
1.2.3 Factors Affecting the Crystal Field Splitting Parameter, $\Delta$ . . . . .	8
1.2.3.1 Spectrochemical Series . . . . .	8
1.2.3.2 Principal Quantum Number, $n$ . . . . .	9
1.2.3.3 Metal Ion Oxidation State . . . . .	9
1.2.4 High- and Low-Spin Complexes . . . . .	10
1.3 Molecular Orbital Theory . . . . .	12
1.3.1 MO Diagram of Molecular Hydrogen . . . . .	13
1.3.2 MO Diagram for $[\text{Co}(\text{NH}_3)_6]^{3+}$ . . . . .	15
1.4 Absorption Spectra of Metal Complexes . . . . .	22
1.4.1 Band Intensity/Selection Rules . . . . .	25
1.4.2 Absorption Spectra of Multi-Electron Systems . . . . .	27
1.5 Magnetic Properties of Metal Complexes . . . . .	33
1.6 Structure and Reactivity of Metal Complexes . . . . .	35
1.6.1 Forward and Reverse Rates and Equilibrium . . . . .	35
1.6.2 Water Exchange Rates for Metal Ions . . . . .	36
1.6.3 Transition State Theory, the Kinetic Rate Constant and Equilibrium . . . . .	38
1.6.4 <i>Trans</i> Effect and Substitution Reactions . . . . .	40
1.6.5 Stability of Metal Complexes . . . . .	44
1.6.6 Chelate Effect . . . . .	46
1.6.7 Macrocyclic Effect . . . . .	50
1.6.8 Hard–Soft Acids–Bases . . . . .	52
1.7 Summary . . . . .	53
Discussion Questions . . . . .	55
Problems . . . . .	55
References . . . . .	57
Further Reading . . . . .	57

<b>2</b>	<b>Metallo-Drugs and Their Action</b>	<b>59</b>
2.1	Introduction	59
2.2	Proteins as Targets for Metallo-Drugs	59
2.2.1	Protein Structure	60
2.2.2	Metal-Binding Sites on Proteins	62
2.3	DNA as a Target for Metallo-Drugs	71
2.3.1	Structure of DNA and RNA	71
2.3.2	Metal-Binding Sites on DNA	74
2.4	Reaction of Metal Complexes in the Biological Milieu	76
2.4.1	Reactions with Chloride	76
2.4.2	Reactions with Phosphate	77
2.4.3	Reactions with Carbonate	77
2.5	Evaluating the Pharmacological Effects of Agents	79
2.5.1	Measuring the Cytotoxicity of a Drug	79
2.5.2	Measuring Drug Uptake	81
2.5.3	Animal Studies	81
2.6	From Discovery to the Clinic	82
2.6.1	Preclinical Phase of the Drug-Approval Process	82
2.6.2	Investigational New Drug (IND) Application	83
2.6.3	Phase I Clinical Trials	83
2.6.4	Phase II Clinical Trials	83
2.6.5	Phase III Clinical Trials	84
2.6.6	New Drug Application	84
2.6.7	Post-Marketing	84
2.6.8	Cost of Research and Development	84
2.7	Summary	85
	Discussion Questions	86
	Problems	87
	References	88
	Further Reading	89
<b>3</b>	<b>Platinum Drugs for Treating Cancer</b>	<b>91</b>
3.1	Introduction	91
3.2	Cisplatin	91
3.2.1	Physical and Chemical Properties of Cisplatin	94
3.2.2	Formulation, Administration, Pharmacokinetics and Adverse Reactions of Cisplatin	96
3.2.3	Reaction of Cisplatin in Blood	97
3.2.4	Uptake (Influx) of Cisplatin by Cells	97
3.2.5	Removal (Efflux) of Cisplatin from Cells: Resistance	99
3.2.6	DNA as a Target for Cisplatin	100
3.2.7	Non-DNA Targets for Cisplatin	109
3.2.7.1	Membrane Proteins	110
3.2.7.2	Zinc Finger Proteins	110
3.2.7.3	Tubulin	111
3.2.7.4	Thioredoxin Reductase	112
3.2.7.5	Stress Response Proteins	112
3.2.7.6	RNA	114

3.3	Carboplatin . . . . .	115
3.3.1	Synthesis and Properties of Carboplatin . . . . .	115
3.3.2	Formulation, Administration, Pharmacokinetics and Adverse Reactions of Carboplatin . . . . .	118
3.3.3	Carboplatin Activation: Breaking the Ring . . . . .	118
3.3.4	Reaction of Carboplatin with Blood Proteins . . . . .	121
3.3.5	Cytotoxicity and Uptake of Carboplatin . . . . .	121
3.3.6	Interaction of Carboplatin with Cellular Targets . . . . .	123
3.4	Oxaliplatin . . . . .	126
3.4.1	Synthesis and Properties of Oxaliplatin . . . . .	126
3.4.2	Formulation, Administration, Pharmacokinetics and Adverse Reactions of Oxaliplatin . . . . .	128
3.4.3	Reaction of Oxaliplatin in Blood . . . . .	128
3.4.4	Uptake of Oxaliplatin by Cells . . . . .	130
3.4.5	Interaction of Oxaliplatin with Cellular Targets . . . . .	130
3.5	Regionally Used Platinum Drugs . . . . .	133
3.5.1	Nedaplatin . . . . .	133
3.5.2	Lobaplatin . . . . .	134
3.5.3	Heptaplatin . . . . .	135
3.6	Platinum Agents in Preclinical Development . . . . .	135
3.6.1	Sterically Hindered Agents . . . . .	135
3.6.2	Compounds with the <i>Trans</i> Geometry . . . . .	136
3.6.3	Biologically Active 'Cargo' Molecules . . . . .	137
3.6.4	Monofunctional Platinum Complexes . . . . .	137
3.6.5	Multinuclear Platinum Compounds . . . . .	137
3.6.6	Platinum(IV) Prodrugs . . . . .	138
3.6.7	Platinum Compounds that do not Attack DNA . . . . .	140
3.6.8	Lipoplatin . . . . .	140
3.7	Summary . . . . .	141
	Discussion Questions . . . . .	143
	Problems . . . . .	144
	References . . . . .	146
<b>4</b>	<b>Anticancer Agents Beyond Cisplatin . . . . .</b>	<b>157</b>
4.1	Introduction . . . . .	157
4.2	Ruthenium Anticancer Agents . . . . .	157
4.2.1	Chemistry of Ruthenium in the Biological Milieu . . . . .	157
4.2.2	Structure, Synthesis and Properties of Ruthenium Antitumor Agents . . . . .	158
4.2.3	Synthesis and Biological Properties of NAMI-A . . . . .	159
4.2.4	Control of Tumor Growth by NAMI-A . . . . .	163
4.2.5	Clinical Trials with NAMI-A . . . . .	163
4.2.6	Interaction of NAMI-A with Potential Biological Targets . . . . .	163
4.2.7	Synthesis and Reactivity of KP1019 . . . . .	165
4.2.8	Anticancer and Biological Activity of KP1019 . . . . .	165
4.2.9	Interaction of KP1019 with Biological Molecules . . . . .	166
4.2.10	Synthesis and Properties of Ruthenium Arene (Half-Sandwich) Compounds . . . . .	168
4.2.11	Biological Activity of the Arene Complexes . . . . .	169

4.3	Gold Anticancer Agents . . . . .	173
4.3.1	Structures, Synthesis and Properties of Gold Anticancer Agents . . . . .	173
4.3.2	Cellular Targets of the Gold Anticancer Agents . . . . .	176
4.4	Titanium Compounds for Treating Cancer . . . . .	181
4.4.1	Structure, Synthesis and Properties of Titanocene Dichloride . . . . .	182
4.4.2	Interaction of Titanocene Dichloride with Potential Biological Targets . . . . .	183
4.4.3	Structure, Synthesis, and Properties of Budotitane . . . . .	183
4.4.4	Antitumor Activity and Clinical Trials with Budotitane . . . . .	184
4.4.5	Biological Interactions of Budotitane . . . . .	184
4.4.6	Titanium Anticancer Drugs in Development . . . . .	184
4.5	Gallium for Treating Cancer . . . . .	187
4.5.1	Chemistry of Gallium in Biological Media . . . . .	187
4.5.2	Structures, Synthesis and Properties of Gallium Anticancer Agents . . . . .	188
4.5.3	Uptake, Cytotoxicity and Reactivity of Gallium Agents in the Biological System . . . . .	189
4.5.4	Gallium Anticancer Agents in Development . . . . .	193
4.6	Other Anticancer Active Metal Complexes . . . . .	194
4.6.1	Palladium . . . . .	194
4.6.2	Osmium . . . . .	196
4.6.3	Rhodium and Iridium . . . . .	199
4.7	Summary . . . . .	201
	Discussion Questions . . . . .	203
	Problems . . . . .	204
	References . . . . .	206
	Further Reading . . . . .	216
<b>5</b>	<b>Responsive Metal Complexes . . . . .</b>	<b>217</b>
5.1	Introduction . . . . .	217
5.2	Prodrug Activation by Redox . . . . .	217
5.2.1	Platinum . . . . .	217
5.2.2	Cobalt . . . . .	220
5.2.3	Copper . . . . .	222
5.2.4	Iron . . . . .	222
5.3	Prodrug Activation by pH . . . . .	225
5.4	Prodrug Activation by Enzymes . . . . .	227
5.5	Prodrug Activation by Light . . . . .	229
5.5.1	Photo-Release of a Cytotoxic Metal Complex . . . . .	229
5.5.2	Photo-Release of Bound Drug Molecules . . . . .	230
5.5.3	Photo-Release of Cell-Signaling Molecules . . . . .	231
5.6	Photodynamic Therapy . . . . .	233
5.6.1	Porphyrins . . . . .	233
5.6.2	Phthalocyanines . . . . .	236
5.6.3	Texaphyrins . . . . .	237
5.6.4	Bacteriopheophorbides . . . . .	237
5.7	Summary . . . . .	237
	Discussion Questions . . . . .	238
	Problems . . . . .	239
	References . . . . .	240
	Further Reading . . . . .	244

<b>6</b>	<b>Metal Complexes for Treating Arthritis and Diabetes</b> . . . . .	<b>245</b>
6.1	Introduction . . . . .	245
6.2	Chemistry of Gold in Biological Media . . . . .	245
6.3	Gold Compounds for Treating Arthritis . . . . .	247
6.3.1	Structures, Synthesis and Properties of Gold Anti-Arthritic Drugs . . . . .	247
6.3.2	Formulation, Administration and Pharmacokinetics of Gold Anti-Arthritic Drugs . . . . .	250
6.3.3	Reactions of Gold Drugs in Biological Media . . . . .	250
6.3.4	Interaction of Gold Drugs with Cellular Targets . . . . .	254
6.3.4.1	Glutathione Reductase . . . . .	258
6.3.4.2	Zinc Finger Proteins . . . . .	258
6.3.4.3	Protein Tyrosine Phosphatases . . . . .	262
6.4	Vanadium Compounds for Treating Diabetes . . . . .	263
6.4.1	Diabetes Mellitus . . . . .	264
6.4.2	Bis(ethylmaltolato)oxovanadium(IV) and Bis(maltolate)oxovanadium(IV) . . . . .	265
6.4.3	Other Vanadium Complexes with Insulin-Mimetic Properties . . . . .	273
6.5	Summary . . . . .	276
	Discussion Questions . . . . .	277
	Problems . . . . .	278
	References . . . . .	279
	Further Reading . . . . .	283
<b>7</b>	<b>Metal Complexes for Killing Parasites, Bacteria and Viruses</b> . . . . .	<b>285</b>
7.1	Introduction . . . . .	285
7.2	Malaria . . . . .	285
7.2.1	Antimalarial Drugs . . . . .	286
7.2.2	Metallo-Antimalarial Agents . . . . .	291
7.3	Leishmaniasis . . . . .	293
7.3.1	Antileishmanial Drugs . . . . .	294
7.3.2	Antileishmanial Drugs in Development . . . . .	296
7.4	American Trypanosomiasis (Chagas Disease) . . . . .	298
7.4.1	Trypanocidal Drugs . . . . .	298
7.4.2	Metallo-Trypanocidal Drugs in Development . . . . .	299
7.5	Human African Trypanosomiasis . . . . .	301
7.6	Tuberculosis . . . . .	301
7.6.1	The Antituberculosis Drug, Isoniazid . . . . .	303
7.6.2	Metallo-Antituberculosis Drugs in Development . . . . .	303
7.7	Peptic Ulcer Disease . . . . .	306
7.7.1	Bismuth Anti-Ulcer Drugs . . . . .	307
7.7.2	Metallo-Anti-Ulcer Drugs in Development . . . . .	309
7.7.3	Metallo-Drugs for Treating Minor Gastrointestinal Disorders . . . . .	310
7.8	Syphilis . . . . .	311
7.9	Bacterial Infections . . . . .	312
7.10	Acquired Immunodeficiency Syndrome (AIDS) . . . . .	314
7.11	Summary . . . . .	318
	Discussion Questions . . . . .	320
	Problems . . . . .	320
	References . . . . .	321

<b>8 Metal Ion Imbalance in the Body</b> . . . . .	<b>329</b>
8.1 Introduction . . . . .	329
8.2 Alzheimer's Disease . . . . .	329
8.2.1 The Amyloid Cascade Hypothesis . . . . .	329
8.2.2 The Metal Ion Hypothesis . . . . .	330
8.2.3 The Oxidative Stress Hypothesis . . . . .	332
8.2.4 Metal-Chelating Agents for Treating Alzheimer's Disease . . . . .	334
8.2.4.1 Clioquinol . . . . .	335
8.2.4.2 Deferiprone . . . . .	336
8.3 Lithium and the Brain . . . . .	337
8.4 Wilson's Disease: Copper Overload . . . . .	338
8.5 Menkes Disease: Copper Deficiency . . . . .	340
8.6 Beta-Thalassemia: Iron Overload . . . . .	342
8.6.1 Desferrioxamine B . . . . .	342
8.6.2 Deferiprone . . . . .	343
8.6.3 Deferasirox . . . . .	343
8.7 Iron-Deficiency Anemia . . . . .	344
8.8 Calcium Imbalance . . . . .	344
8.9 Chelation Therapy . . . . .	346
8.10 Summary . . . . .	348
Discussion Questions . . . . .	349
Problems . . . . .	350
References . . . . .	351
Further Reading . . . . .	356
<b>9 Metal Complexes for Detecting Disease</b> . . . . .	<b>357</b>
9.1 Introduction . . . . .	357
9.2 Technetium in Diagnostic Nuclear Medicine . . . . .	358
9.2.1 Clinically Used $^{99m}\text{Tc}$ Imaging Agents . . . . .	361
9.2.2 Technetium Drugs for Selective Targeting . . . . .	366
9.2.3 Innovations in Synthesis: The $[\text{Tc}(\text{CO})_3]^+$ Core . . . . .	368
9.3 Metal Compounds as Contrast Agents for MRI . . . . .	371
9.3.1 Clinically Used MRI Contrast Agents . . . . .	376
9.3.1.1 Magnevist . . . . .	377
9.3.1.2 Dotarem . . . . .	378
9.3.1.3 Ablavar . . . . .	378
9.3.1.4 Teslascan . . . . .	380
9.3.2 Contrast Agents in Development . . . . .	381
9.4 Radiotherapy . . . . .	382
9.5 Summary . . . . .	386
Discussion Questions . . . . .	387
Problems . . . . .	387
References . . . . .	389
Further Reading . . . . .	393
<b>10 Nanomedicine</b> . . . . .	<b>395</b>
10.1 Introduction . . . . .	395
10.2 Circulation, Uptake, and Elimination of Nanoparticles . . . . .	396

10.2.1	The Mononuclear Phagocyte System . . . . .	396
10.2.2	Enhanced Permeation and Retention (EPR) Effect . . . . .	399
10.2.3	Cell-Targeting Groups . . . . .	400
10.2.4	Uptake of NPs by Cells . . . . .	401
10.2.4.1	Endocytosis . . . . .	401
10.2.4.2	Silver Nanoparticles . . . . .	401
10.2.4.3	Gold Nanoparticles . . . . .	401
10.2.4.4	Carbon Nanotubes . . . . .	403
10.2.4.5	Superparamagnetic Iron Oxide Nanoparticles . . . . .	404
10.2.4.6	Mesoporous Nanoparticles . . . . .	404
10.2.4.7	Quantum Dots . . . . .	404
10.2.4.8	Metal Organic Frameworks . . . . .	406
10.2.5	Biodistribution of Nanoparticles in the Body . . . . .	406
10.3	Nanoscience for Treating Cancer . . . . .	407
10.3.1	Gold Nanoparticles . . . . .	407
10.3.2	Mesoporous Silica Nanoparticles (MSNPs) . . . . .	414
10.3.3	Nano Metal–Organic Frameworks (NMOFs) . . . . .	417
10.4	Nanoparticles for Detecting Disease . . . . .	419
10.4.1	Magnetic Resonance Imaging (MRI) . . . . .	419
10.4.2	Fluorescence Spectroscopy (FL) . . . . .	421
10.5	Theranostic Nanoparticles . . . . .	426
10.6	Cytotoxicity of Nanoparticles . . . . .	428
10.7	Summary . . . . .	429
	Discussion Questions . . . . .	431
	Problems . . . . .	432
	References . . . . .	433
<b>Index</b>	. . . . .	<b>441</b>